← Back to Clinical Trials
Recruiting NCT07520032

NCT07520032 Effectiveness of Extra-corporeal Shockwave Diathermy in the Management of Upper Limb Function Patients With Stroke.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07520032
Status Recruiting
Phase
Sponsor Gulf Medical University
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2025-10-30
Primary Completion 2026-05-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
ESWTStretchingMobility

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 50 participants in total. It began in 2025-10-30 with a primary completion date of 2026-05-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Stroke is a leading cause of death and disability worldwide. A major complication of stroke is spasticity, marked by increased muscle tone and impaired movement. It affects majority stroke patients and complicates rehabilitation, affecting the upper limb function of survivors. While traditional treatments like oral medications and botulinum toxin injections offer some relief, they have notable limitations, causing the need for novel, non-invasive approaches. Extracorporeal shock wave therapy (ESWT), which uses acoustic waves for regeneration and neuromodulation, has shown promise in reducing spasticity with minimal side effects, though its precise mechanisms and ideal protocols need further study. Current evidence supports ESWT's efficacy and safety, often matching established treatments, but gaps remain regarding standardized application and long-term functional outcomes, highlighting the need for more robust research.

Eligibility Criteria

Inclusion criteria: 1. Diagnosed as 1st stroke incidence 6 months back 2. Both male and female 3. Age 25 to 65 years 4. the ability to follow verbal instructions 5. Modified Ashworth Scale score 1-4 Exclusion criteria: 1. Recurrent stroke. 2. Severe contractures or deformities of upper extremity. 3. Chronic pain affecting upper extremity function. 4. malignant tumor, pacemakers, infection

Contact & Investigator

Central Contact

Sharmila banu Ali, DPT

✉ sharmieashak@gmail.com

📞 067031555

Principal Investigator

Sharmila banu Ali, DPT/MPT

PRINCIPAL INVESTIGATOR

Thumbay Physical Therapy and Rehabilitation Hospital

Frequently Asked Questions

Who can join the NCT07520032 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07520032 currently recruiting?

Yes, NCT07520032 is actively recruiting participants. Contact the research team at sharmieashak@gmail.com for enrollment information.

Where is the NCT07520032 trial being conducted?

This trial is being conducted at Ajman, United Arab Emirates.

Who is sponsoring the NCT07520032 clinical trial?

NCT07520032 is sponsored by Gulf Medical University. The principal investigator is Sharmila banu Ali, DPT/MPT at Thumbay Physical Therapy and Rehabilitation Hospital. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology